94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Infectious Diseases
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1508470
This article is part of the Research Topic Aquatic Animal Health and Epidemiology: Disease Surveillance, Prevention and Control View all 7 articles
Utilizing shRNA-expressing lentivectors for viral hemorrhagic septicemia virus suppression via NV gene targeting
Provisionally accepted- Department of Genetics, Shahrekord University, Shahrekord, Iran
Background: Viral hemorrhagic septicemia virus or VHSV, is a single-stranded negative-sense RNA virus that is a member of the Rhabdoviridae family's genus Novirhabdovirus. Its major host is rainbow trout. Severe clinical symptoms and a higher mortality rate in fish populations are caused by this virus.Regretfully, there is currently no medication or vaccination available to treat it. Recently, there has been a lot of interest in developing antiviral therapies employing interfering RNA (RNAi), particularly shRNA. This study used shRNAs targeting the NV gene of VHSV to test its effectiveness in preventing VHSV proliferation in cell culture. Using the VHSV-Fil3 strain, the appropriate oligonucleotide sequence for NV gene coding was chosen for this purpose. Subsequently, shRNA molecules were designed and synthesized with the aid of shRNA design tools. The shRNAs were transfected into HEK293T cells after being cloned into the suitable vectors using the third generation of lentiviral packaging system. The CS2-2 cell line was subsequently transduced with these shRNA-expressing lentiviruses in order to challenge the VHS virus. Finally, TCID50 was employed to calculate the viral infectious titer in order to assess the effectiveness of shRNAs.Results: According to the final calculations, all shRNAs exhibited antiviral activity. When compared to the control groups, the shRNAs 1, 2, and 3 considerably lowered VHSV output in the TCID50 test (nearly 99.99%, 99.99%, and 99.99%, respectively, compared to cells with VHSV inoculation and nearly 99.98%, 99.98%, and 99.97%, respectively, compared to cells with VHSV and scrambled vector inoculation).Thus, it can be declared that RNA interference (RNAi) has the potential to be an exceptionally effective therapeutic option against viruses like VHSV.
Keywords: VHSV, NV, RNAi, shRNA, Lentiviral vector, TCID50
Received: 09 Oct 2024; Accepted: 18 Mar 2025.
Copyright: © 2025 Pourhoseini Dehkordi, Saffar, Mokhtari, Asadi Samani and Amini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Behnaz Saffar, Department of Genetics, Shahrekord University, Shahrekord, Iran
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.